Back to Search
Norethin 1/35E-21
by Watson Pharmaceuticals Inc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa IncContraceptionCOCP
DiscontinuedGeneric

Estrogen

Ethinyl Estradiol

0.035Mg

Progestin

Norethindrone

1Mg

Regimen Protocol

Monophasic 21 day

Androgenicity

Moderate

Approval Date

4/12/1988

Additives
None
Active Alternative Brands
Alternative brands with the same formulation that are actively prescribed

Glenmark Pharmaceuticals Inc., USA

Alyacen 1/35

Northstar Rx LLC

Dasetta 1/35

Naari Pte Ltd

Norethindrone And Ethinyl Estradiol

Watson Laboratories Inc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc

Norethindrone And Ethinyl Estradiol

Barr Laboratories Inc

Nortrel 1/35-21

Barr Laboratories Llc (An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc)

Nortrel 1/35-28

Aurobindo Pharma Limited

Nylia 1/35

Have clinical questions about Norethin 1/35E-21?

Get evidence-based, cited answers from our AI co-pilot for hormone health.

Try Dama Assist

© 2026 Dama Health. All rights reserved.

This tool is intended for use by licensed healthcare professionals. It provides reference information on FDA-approved contraception and hormone therapy products. Results should not be used as a substitute for clinical judgment. Data is sourced from the FDA Orange Book and other FDA-sourced resources and may contain errors or omissions.

Last updated: July 2025 | Powered by Dama Health | Terms of Use | Privacy Policy